BioAtla faces Nasdaq delisting after listing council affirms suspension decision

• Nasdaq Listing Council affirmed a decision to delist BioAtla’s common stock from Nasdaq.
• Delisting stems from non-compliance with the $1 minimum bid price rule and failure to meet the $2.5 million stockholders’ equity standard.
• Trading is set to be suspended at the open on Aug. 31, 2026 unless the Nasdaq Board elects to review.
• A Form 25-NSE is expected to be filed with the SEC to remove the shares from Nasdaq listing and registration.
• Shares are expected to become eligible for OTC Markets quotation under symbol BCAB, risking lower liquidity and price pressure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioAtla Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001539497-26-002373), on August 28, 2026, and is solely responsible for the information contained therein.